Association of Cholinesterase Inhibitor–Memantine Combination Therapy With Long-Term Community Management and Mortality in Patients With Dementia: A Nationwide Retrospective Cohort Study
Dementia and Neurocognitive Disorders · 2026 · 25 (4) · 253
DOI: 10.12779/dnd.2026.25.4.253 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Dementia and Neurocognitive Disorders, 2026. Verfasst von Hyuk Sung Kwon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hyundai Pharmaceutical Co., Ltd..
Themen: Demenz
Abstract (Originalsprache)
Background and Purpose: Long-term real-world outcomes of acetylcholinesterase inhibitor (AChEI)-memantine combination therapy remain uncertain. We evaluated treatment patterns and associations of combination therapy with 5-year community management and mortality in patients with dementia.
Methods
Using customized Korean National Health Insurance Service data, we identified patients newly diagnosed with dementia from 2003 to 2018. The main analysis included patients who had not received memantine during the first year after diagnosis but initiated it thereafter. Five-year community management and all-cause mortality were compared between memantine monotherapy and AChEI-memantine combination therapy and examined according to combination-therapy duration.
Results
Among 942,068 patients, 552,945 (58.7%) received anti-dementia medication; treatment use increased from 25.5% in 2003 to 73.1% in 2018. Among later memantine initiators, 89,747 received combination therapy and 29,426 received monotherapy. Combination therapy was associated with higher 5-year community management (46.7% vs. 32.5%; absolute difference, 14.2 percentage points; p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
- Department of Statistics, GN Co., Seoul, Korea.
- Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
- Department of Neurology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
- Department of Neurology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
ORCID-Profile: Hyuk Sung Kwon, Jung-Ook Shin, Geun U Park, Geon Ha Kim, YoungSoon Yang, Chan-Nyoung Lee, Hojin Choi
Förderung
- Hyundai Pharmaceutical Co., Ltd.
Zitieren
APA
Kwon, H. S., Shin, J. O., Park, G. U., Kim, G. H., Yang, Y., Lee, C. N., & Choi, H. (2026). Association of Cholinesterase Inhibitor–Memantine Combination Therapy With Long-Term Community Management and Mortality in Patients With Dementia: A Nationwide Retrospective Cohort Study. Dementia and Neurocognitive Disorders, 25(4), 253. https://doi.org/10.12779/dnd.2026.25.4.253
Vancouver
Kwon HS, Shin JO, Park GU, Kim GH, Yang Y, Lee CN, et al. Association of Cholinesterase Inhibitor–Memantine Combination Therapy With Long-Term Community Management and Mortality in Patients With Dementia: A Nationwide Retrospective Cohort Study. Dementia and Neurocognitive Disorders. 2026;25(4):253. doi:10.12779/dnd.2026.25.4.253
BibTeX
@article{Kwon2026,
author = {Kwon, Hyuk Sung and Shin, Jung-Ook and Park, Geun U and Kim, Geon Ha and Yang, YoungSoon and Lee, Chan-Nyoung and Choi, Hojin},
title = {Association of Cholinesterase Inhibitor–Memantine Combination Therapy With Long-Term Community Management and Mortality in Patients With Dementia: A Nationwide Retrospective Cohort Study},
journal = {Dementia and Neurocognitive Disorders},
year = {2026},
volume = {25},
number = {4},
pages = {253},
doi = {10.12779/dnd.2026.25.4.253}
}
EUVIMED